PASADENA, Calif., Feb. 13, 2013 /PRNewswire/ -- Immunotech
Laboratories, Inc. ( PINKSHEETS : IMMB) Announced
$2M Funding approval from Bulgarian
Immunotech Partnership Company (Immunotech BG) to begin
clinical trials for HIV-AIDS advanced stages.
Immunotech's associate company in Bulgaria (Immunotech BG) today confirmed the
negotiations with two of the largest Bulgarian Hospitals for
the start of Clinical Trials for the US Company's patented IPF-ITV
and IPF-ITV Phases on 50 advanced stage patients.
Immunotech Director Bo Linton
today commented "We believe that in both cases, the results will be
very encouraging, as to this point we have already applied the
medicine with volunteers and the results have been highly
successful in Bulgaria, where the
use of the vaccine labeled as an 'Experimental Drug' is permitted.
The results of the Clinical Tests in Bulgaria should significantly help Fast-Track
the FDA approval process in the USA, with the ultimate goal of the IPF
medicines being available for treatment of HIV-AIDS patients in the
USA."
Company President Harry Zhabilov
stated, "The clinical trials in Bulgaria are scheduled to begin in
March 2013 and will end in
August 2013, which will give us the
necessary results to receive approval for increased application for
mass distribution for our IPF medicine."
Immunotech Laboratories BG will provide the necessary funding up
to $2M for all of the above mentioned
activities and contracts and all necessary related to the project,
including in the USA.
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to
the commercialization of its proprietary proteins for the treatment
of debilitating infectious diseases such as HIV, Cancer, Hepatitis
and Aids. Immunotech is committed to creating drugs for the better
health of mankind.
Safe Harbor Statement: This news release contains
forward-looking statements that involve risks and uncertainties
associated with financial projections, budgets, milestone
timelines, clinical development, regulatory approvals, and other
risks described by Immunotech Laboratories, Inc. from time to time
in its periodic reports filed with the SEC. IPF is not approved by
the US Food and Drug Administration or by any comparable regulatory
agencies elsewhere in the world. While Immunotech Laboratories
believes that the forward-looking statements and underlying
assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the
ability of Immunotech Laboratories to establish the efficacy of IPF
in the treatment of any disease or health condition, the
development of studies and strategies leading to commercialization
of IPF in the United States, the
obtaining of funding required to carry out the development plan,
the completion of studies and tests on time or at all, and the
successful outcome of such studies or tests. Therefore, there can
be no assurance that the forward-looking statements included in
this release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, Immunotech Laboratories or any other person that the
objectives and plans of Immunotech Laboratories will be achieved
should not regard the forward-looking statements as a
representation.
Company Contact: info@immunotechlab.com
Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup
SOURCE Immunotech Laboratories, Inc.